Cyclerion Therapeutics (CYCN) FCF Margin (2019 - 2025)
Historic FCF Margin for Cyclerion Therapeutics (CYCN) over the last 6 years, with Q3 2025 value amounting to 30.17%.
- Cyclerion Therapeutics' FCF Margin rose 8543600.0% to 30.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 48.16%, marking a year-over-year increase of 31652400.0%. This contributed to the annual value of 216.65% for FY2024, which is N/A changed from last year.
- According to the latest figures from Q3 2025, Cyclerion Therapeutics' FCF Margin is 30.17%, which was up 8543600.0% from 540.86% recorded in Q2 2025.
- Cyclerion Therapeutics' 5-year FCF Margin high stood at 19.93% for Q4 2024, and its period low was 23314.52% during Q1 2021.
- For the 4-year period, Cyclerion Therapeutics' FCF Margin averaged around 3215.02%, with its median value being 1195.06% (2025).
- In the last 5 years, Cyclerion Therapeutics' FCF Margin plummeted by -202982400bps in 2021 and then surged by 215093100bps in 2022.
- Over the past 4 years, Cyclerion Therapeutics' FCF Margin (Quarter) stood at 1619.14% in 2021, then plummeted by -118bps to 3535.29% in 2022, then surged by 101bps to 19.93% in 2024, then crashed by -251bps to 30.17% in 2025.
- Its FCF Margin stands at 30.17% for Q3 2025, versus 540.86% for Q2 2025 and 1195.06% for Q1 2025.